Danish bioinformatics platform PipeBio acquired by US-based Benchling

Benchling, a cloud-based platform for biotech R&D, has acquired the Danish company PipeBio to accelerate AI-powered antibody discovery. Mazanti-Andersen advised PipeBio in connection with the sale. 

Founded in 2020 and based in Horsens, Denmark, PipeBio is a cloud-based bioinformatics platform that enables scientists to screen and analyze millions of sequences, helping them identify key candidates for biologics development. The platform excels at high-throughput antibody screening, data visualization, and hit selection, making it a valuable asset for researchers developing new therapeutics.

With this acquisition, PipeBio aims to leverage Benchling’s extensive resources and integration capabilities to refine its offerings. The collaboration is expected to improve the efficiency of the discovery process by combining PipeBio’s advanced sequence analysis tools with Benchling’s established software ecosystem. 

Mazanti Transactions advised PipeBio in all aspects of the transaction with a team comprising of Frederik B Hasling, Christian Geertsen, Mette Gahrn-Jensen, Daniel Hedme og Daniel Stückler.

Read more here.